EASD 2026: Orforglipron shows an efficacy edge over oral semaglutide in T2D - Pharmaceutical Technology

Orforglipron shows modestly greater weight and HbA1c reductions than oral semaglutide, supporting its potential in type 2 diabetes. Orforglipron shows modestly greater weight and HbA1c reductions than oral semaglutide, supporting its potential in type 2 diabetes. Findings presented at EASD 2026 support orforglipron as a competitive oral GLP-1 option in T2D, combining strong glycemic and weight-loss efficacy with simpler daily administration. Image Credit: Shutterstock/[Simple Cam] Unlock FREE Access to Premium Content ​Discover exclusive forecasts, analyst insights, and in-depth pharmaceutical industry analysis spanning drug development, manufacturing, regulation, and global healthcare trends. With a free Pharmaceutical Technology profile, you can: The leading…

Source: Pharmaceutical Technology